her2

News

Mersana stung by FDA hold on STING drug

A patient death in a phase 1 trial of Mersana Therapeutics’ antibody-drug conjugate XMT-2056 has resulted in the FDA formally placing the study on clinical hold.<

News
Daiichi

EU clears Enhertu for HER2-low breast cancer

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be

News
Jazz_Pharma_logo

Jazz swings on ASCO-GI data for zanidatamab

Jazz Pharma's $325 million gamble on rights to Zymeworks' HER2-directed bispecific antibody zanidatamab was the largest in its history, and seems like a safer bet after a mid-stage readout